GSC
BDRX

Ground Swell Capital’s Biodexa Pharmaceuticals BDRX Stock Holding History

Ground Swell Capital’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$11.7K – 171
2024
Q2 		$11.7K Buy
+10
New +$13.1K 0.01% 149

Other funds holding BDRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Ground Swell Capital's BDRX Position: Q3 2024 in Review

Ground Swell Capital sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2024, closing a stake of 10 shares — an estimated $11.7K sold.

Ground Swell Capital first reported a position in BDRX in Q2 2024 and held it in 1 quarter. The position peaked at $11.7K in Q2 2024. 5 funds tracked by Wall St. Rank hold BDRX as of Q3 2024.

  • Ground Swell Capital reported no remaining Biodexa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Ground Swell Capital sold 10 Biodexa Pharmaceuticals shares in Q3 2024, an estimated $11.7K.
  • Ground Swell Capital first reported a position in Biodexa Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Ground Swell Capital's Biodexa Pharmaceuticals position peaked at $11.7K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2024.

Based on Ground Swell Capital's 13F filing for Q3 2024, filed 29 Oct 2024.